

Research Article**Immunohistochemical aspects on (IL-6) and its relationship to pathological parameters and hormones receptors (ER, PR, HER-2) in breast cancer (BC) women from south of Iraq***Alaa R.Rashed¹, Maha K.Ibrahim², Maha SH. Hassan³*¹Education collage, Thi-qar university²Science collage/ Basrah university³harmacy collage Thi-qar university**ABSTRACT:**

The aim of this study was to review the observations and information on relationship of preoperative level of (IL-6) with hormones receptors (ER,PR,HER-2) and the expression of these receptors in biopsies from patients with different stages and grades of disease by immunohistochemical method. In this study total number of (130)cases was analyzed and most patients diagnosed with stage (S111) then (S11)and (S1) with highly significant difference at ($p \leq 0.05$) and the same results was obtained from classified tumor grading with (BC)patients. The recent study evaluated level of (IL-6) in all (BC)patients ,the data showed highly significant difference and the mean level was increased in (71)case compared to control ,also we evaluated the relationship between tumor staging and grading with level of (IL-6) and data revealed to high level in (S111) patients while no signification between (S1,S3) ,the same results recorded between tumor grading and level (IL-6). Hormones receptors expression (ER,PR,HER-2) and its correlation with (IL-6)level was also determined ,the (IL-6) with (ER+)compared to (ER-) with high significance ($p=0.00$),the same results shown with (PR+) and(HER-2) expression and (IL-6)in all (BC)patients. The role of (IL-6) in (BC) immunity ,carcinogenesis ,cancer pathogenesis ,tumor initiation ,growth and metastasis .Results also explained correlate of (IL-6)with clinical staging and grading ,these findings Pointed to an important role in the progression of (BC) at least in patients with advanced disease stages.Data determined that the (ER+)positive tumor more reactive with(IL-6)then (PR+),(HER-2) which explained the effect of this factor on hormones receptors. Moreover present study found that the level of (IL-6) in (BC)recurrence may be differ according to(HER-2)status ,positive association with(BC) recurrence only among (HER2-)tumor with high mean level as compared to patients with(HER2+).Immunohistochemical staining was used in this study and results showed variable degree of staining Within invasive ductal and lobular carcinoma types compared to control.

1- Introduction

Breast cancer is a complex and multifactorial disease resulting from abnormal growth of cells begins in the lining layer of duct or lobe of the breast. that leads to malignant tumor formation . It is the commonest malignancy in women, affecting women during their lifetime .Bc, considered the most common cancer, is now leveled as the first among all cancers diagnosed in women (Kolahdoozan, *etal*, 2010; Ferlay *et al.*, 2015).(IL-6)is a cytokines and consider as pleiotropic inflammatory cytokines produced by neutrophil and from macrophages, monocytes, T-cells, B-cells and fibroblasts, endothelial cells, osteoblasts and tumor cells(Salgado,*etal*,2003 Kishimoto 2006; Fields , 2009; Guillermo, and Descoteaux,2014)(). IL-6 plays a chief role in pathogenesis and progress of malignancies. It helps tumor to grow through inhibiting apoptosis of cancer cells and the stimulation of tumor angiogenesis,(Salgado, et al.,2003),also IL-6 contributes to the proliferation of many cancer cells and, especially those at the advanced stage of development, IL-6 concentrations can depend on the clinical tumor stage and histological tumor grade (Brozek ,*etal*.,2005).most commonly elevated in patients with endometrial cancer, lung cancer, colorectal cancer breast cancer and ovarian carcinoma.(Zakrzewska and Pozański,2001 Salgado, *et al.*,2003;Songur,*etal*.,2004;Bellone,*etal*.,2005).However IL-6

overexpression was found in breast carcinoma and in prostate cancer (Garcia,*etal*.,2005;Culig,*etal*.,2005). The ovarian steroid hormones progesterone and estrogen play critical roles in the development and progression of breast cancer and endometriosis(Shao *et al.*, 2014).Estrogen receptor and progesterone receptor, along with human epidermal growth factor receptor 2 (HER2), are used to classify phenotypes in breast cancers and to predict response to specific therapies(Cadoo *et al* .,2013).Bc is a heterogeneous disease, and its prognosis may depend on characteristics of tumor (Onitilo,*etal*.,2009).Therefore, the roles of IL-6 related markers in mediation of tumor growth and metastasis could be influenced by distinct subtypes that have been identified on the basis of gene or protein expression in tumor tissue (Seruga ,*etal*.,2008),different breast cancer subtypes may produce distinct inflammatory mediators, which may affect their distinct tumor progression pathways (Gonzalez,*etal*.,2011; Levano,*etal*.,2011),so this study have focused on the use of IL-6 as a prognostic factor for breast cancer.

Material and mothed**Sample collection**

In this study total number of (130)cases was analyzed and (60) cases were subjected to Histopathological and

Immunohistochemical studies. The recent study evaluated level of (IL-6) in all (BC) patients and (16)control ,the data showed highly significant difference and the mean level was increased in (71)case compared to control

Immunological studies: In this study we measured IL-6 level in the serum of the breast cancer patients by using Enzyme-Linked Immuno Sorbent Assay (ELISA) , human (IL-6) ELISA kit.

Histopathological studies: the histopathological study of tumor stage was assessed according to the criteria established by the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual as SI, SII and SIII , while the tumor grade was determined according to the Scarff-Bloom-Richardson classification modified by Elston and Ellis also as GI,GII and GIII.

Immunohistochemstiry: Hormone receptors(ER,PR and HER-2) were assessed via immunohistochemistry mothed (IHC) .

Statistical analysis: The data of this study were analytic with one way anova ,t-test and chi-square by using Spss program version 22.

Results:

1- Clinical staging and histologic grading

Dependent on Tumor-node-metastasis (TNM) system was used to classified the stage of BC, in our patients out of (130) cases , staging system can be applied only to (60) cases , this study had reported (1)cases (1.7%) diagnosed as stage I, (28) cases with (46.7%) are clarified as stage II and (31) cases with (51.7%) are stage III, there were a significant differences among different stages at($P \leq 0.05$),(table1).

Table (1) :Types of tumor histologic staging in (BC) patients.

Staging	no. of patients	Percentage rate%
Stage I	1	1.7%
Stage II	28	46.7%
Stage III	31	51.7%
Total	60	100%

Chi-square = 27.30 df= 3 p- value = 0.00


In this study grading system can be applied only to 60 cases , and we find that 2 cases (3.33%) were diagnosed as grade I, 30 cases with (50 %) are grade II, and 20 cases with (46.67%)recorded as grade III. There was a significant differences among different grades ($P \leq 0.05$) , table (4-10).

Table (2): Tumor grading in (BC) patients.

Grade	no. of patients	Percentage rate %
Grade I	2	3.33%
Grade II	30	50%
Grade III	28	46.67%
Total	60	100%

Chi-square = 24.40 df= 2 p- value = 0.00

2-Estrogen and progesterone receptors



Alaa R.Rashed et.al / Immunohistochemical aspects on (IL-6) and its relationship to pathological parameters and hormones receptors (ER, PR, HER-2)in breast cancer (BC)women from south of Iraq

There are (40) patients were positive for ER,(66.7%) distributed according scoring system, while only (20) of patients were negative for this receptor(33.3%), the difference between the two percentages was significant ($P > 0.05$), Table(3) Figure(1).

Figure 1. Breast Invasive Duct Carcinoma, LuminalA Subtype Showing Positive Nuclear Immunostainingfor ER (A) Negative (B), 1+ (C)2+(D)3+(E)4+(F)5+(G)6+ Magnification x400

Table (3): BC patients distributed by the expression of estrogen receptor.

Hormone receptor	No.	Percentage rate%
ER positive	40	66.7%
ER negative	20	33.3%
Total	60	100%

$X^2 = 6.67$ $df = 1$ $p\text{-value} = 0.010$

While (45)cases were positive for PR (75%) and (15) cases were (25%) significant ($P > 0.05$), Table (4)Figure(2).




Figure 2. Breast Invasive Ductal Carcinoma, LuminalA Subtype Showing Positive Nuclear Immunostainingfor PR (A) Negative (B), 1+ (C)2+(D)3+(E)4+(F)5+ Magnification x400

Table (4): BC patients distributed by the expression of progesterone receptor.

Hormone receptor	No.	Percentage rate%
PR positive	45	75%
PR negative	15	25%
Total	60	100%

$X^2 = 15.00$ $df = 1$ $p\text{-value} = 0.00$

3- HER-2

Result found (33)cases were positive (55%),and(27) cases were negative (45%) of patients, the percentage of cases of breast tumor were significant ($P > 0.05$) Table (5) Figure(3)

Table (5): BC patients distributed by the expression of human epidermal growth factor-2 receptor.

HER-2	No.	Percentage rate%
Positive	33	55%
Negative	27	45%
Total	60	100%

$\chi^2 = 0.60$ df= 1 p- value = 0.43




Figure 3. Breast Invasive Ductal Carcinoma, LuminalA Subtype Showing Positive Nuclear Immunostaining for HER2 (A) Negative (B), 1+ (C)2+(D)3+(E)4+ Magnification x400

3- Evaluation of 6 (IL-6) levels

The data showed elevated level of IL-6 in (BC) patient reached to (41.2732 pg/ml), as compared to control that the level of (IL-6) was (.2254pg/ml), with significant difference ($p > 0.05$) Table (6).

Table (6) Serum levels of (IL-6) in BC patients groups and healthy the result expressed as (mean \pm SE) .

Groups	No.	Mean of IL-6 pg/ml	SE \pm	Percentage rate %
patient	71	41.2732	6.99329	.000
control	16	.2254	.00907	

4- Correlation between (IL-6) level and staging and grading

Also the study determined the relationship between tumor staging and level of (IL-6) mean levels The results showed highest level was in patients at stage3(S3) that the (IL-6) level reached to (76.5465pg/ml), while the patients from S2 the (IL-6) level was (13.9293pg/ml), and reached to (8.3400 pg/ml) in patient from (S1), statistically no significant difference observed between (S1,S2) and no significant difference also between (S1 , S3) when (IL-6) level compared ,but high significant difference was recorded between (S2,S3) at ($P=0.000$), Table(7).

Table(7): Concentration of IL-6 in relation to tumor stage in (BC) patients. values expressed as (Mean \pm S.E.)

Tumor staging	no .of patient	Concentrate of(IL-6) pg/ml	Sig. between groups	P value
Stage1(S1)	2	8.3400 \pm .01000	S1-S2	.896
Stage 2(S2)	28	13.9293 \pm 4.86047	S1-S3	.114
Stage 3(S3)	31	76.5465 \pm 13.88997	S2-S3	.000

Alaa R.Rashed et.al / Immunohistochemical aspects on (IL-6) and its relationship to pathological parameters and hormones receptors (ER, PR, HER-2)in breast cancer (BC)women from south of Iraq

Also the results showed high significant increased with(IL-6) levels in G3 patients that the mean level was (57.1746pg/ml) ,(19.9030 pg/ml) and(19.9030 pg/ml) in patient whose diagnosed with(G2,G1) , respectively, also no significant difference between (G1,G2) and(G1,G3) but high significant difference recorded between (G2,G3)at (p=0.010) (Table8).

Table(8): Concentration of IL-6 in relation to tumor stage in (BC) patients. values expressed as (Mean ± S.E.)

Tumor grading	no. of cases	Concentrate of(IL-6) pg/ml	Sig.between groups	P value
Grade1(G1)	2	5.0050±3.32500	G1-G2	.705
Grade2(G2)	30	19.9030±5.14490	G1-G3	.189
Grade3(G3)	28	57.174±13.63024	G2-G3	.010

5-Correlation between (IL-6) level and (ER,PR,HER2) receptor expression

Data and figures from this study indicated to the relationship between (IL-6) level and expression of each receptor in (BC) patients ,the result showed increased with(IL-6) level reached (56.3145 pg/ml± 11.14360pg/ml) with(ER+)comparative with(ER-) which the (IL-6)level was (19.1690±6.53831 pg/ml) at high significant differences(p=.000), Table(4) and increased in PR+(62.5028 pg/ml) as compared with PR-(11.6953 pg/ml) also with high significant differences(p=.000), Table(5) while the result showed increased mean level of (IL-6) with Her2-(62.6413 pg/ml) as compared with Her2+(27.8280 pg/ml) Table(9) and Table(10)

Table(9)increased mean serum level of(IL-6) with(ER) receptor. Result expressed as (mean ±SE)

Receptors type	no.of patient	(IL-6) levels pg/ml	SE	T	Df	P value
ER+	40	56.3145	11.14360	2.254	58	.000
ER-	20	19.1690	6.53831			

Table(10): increased mean serum level of(IL-6) with PR receptor. Result expressed as(mean ±SE)

Receptors type	no.of patient	(IL-6) levels pg/ml	SE	T	Df:	P. value
PR+	45	62.5028	10.35058	2.781	58	.000
PR-	15	11.6953	5.16183			

Table(6): Level of(IL-6) and (HER2) receptor. Result expressed as (mean ±SE)

Receptors type	No.of patien.	(IL-6) levels pg/ml	SE	T	Df	P value
HER2+	33	27.8280	8.40926	2.235	58	=.007
HER2-	27	62.6413	13.83570			

Discussion

IL-6 in breast cancer

Our data was found high level of (IL-6) with significant difference in all (BC) patients compared with its concentration in healthy women, this may be to the role of (IL-6) with (BC) and the cancerous cells that produce it in addition to the inflammatory cells from the surrounding tissue, this results in agreement with other studies by CG, *et al.*, (2003) which displayed the patients with BC had showed high level of IL-6 and more less than in healthy group, also agreed with other study made by Victor P., *et al.*, (2015) who observed an association of levels IL-6, and IL-10 in (BC) patients with or without receiving chemotherapy, the high proinflammatory cytokine IL-6 mRNA expression in most patients without chemotherapy was (10.8447) due to the production of cancer cells and cells surrounding the tumor tissue. Furthermore our findings close to study of Hong DS, *et al.*, (2007) and Salgado R, *et al.*, (2003) they found high levels of circulate IL-6 associate with the numeral of metastatic sites and IL-6 promotes the formation of distant metastasis, previous study done by Cho YA, *et al.*, (2013) indicated that inflammation within the tumor microenvironment may play an important role in breast cancer progression this displayed the mean value of IL-6 of breast cancer patients without receiving chemotherapy was statistically significant higher than in patients with chemotherapy, The role of IL-6 in breast cancer immunity and carcinogenesis has been well established, its play diverse roles in cancer pathogenesis, with increasing evidence suggesting their involvement in tumor initiation, growth and metastasis Smyth MJ, *et al.*, (2004), the (IL-6) produced from tumor cells and normal cells and it is considered as stimulators for angiogenesis as well as factor for cancer cell growth and proliferation (Salgado *et al.*, 2003; Victor *et al.*, 2015).

IL-6 levels correlation with clinical stage and histologic grade

Present study proved the relationship between mean level of (IL-6) in serum of all (BC) patients that diagnosed with S(III), then S(II) and the lowest level was measured in patients with (SI), this results may be related to late stage of tumor growth and all patients (mastectomy) so this factor correlate with clinical stage and this in agreement with other researchers who showed that there was detectable correlation between stage and the levels of (IL-6), and high level was frequently in S(III) than in S(I and II), it produced by tumor cells and it has able to promote tumor growth by up-regulating anti apoptotic and angiogenic proteins in tumor cells Ordemann *et al.*, (2002); Kozlowski *et al.*, (2003); Fuksiewicz M, *et al.*, (2006), the level of IL-6 has a positive correlation with TNM staging system of breast cancer thus indirectly correlating with the prognosis of the patient with breast cancer, and this agree with Chavey C, *et al.*, (2007) .may be illustrated that the (IL-6) level was increased with tumor grading and invasiveness of tumor

cells and associated with tumor progression to be more malignant, these results deal with other studies indicated to high level of (IL-6) with G3 (Kozlowski *et al.*, (2003); Mousa, (2014) ; Sherif A., *et al.*, (2016); furthermore these results support with study made by Mousa, (2014) on patients with bladder cancer who showed a high significant increased mean levels of IL-6 in patients with G3 tumor as compared with patients with G1 and G2, IL-6 is produced by a variety of tumor cell lines and is associated with many changes as auto and paracrine stimulation of tumor cells proliferation, with the upregulation of anti-apoptotic proteins, and with the induction of pro-angiogenic cytokines, these changes may parallel the tumor cell progression toward a more malignant phenotype, secrete of IL-6, which stimulates the growth and invasiveness of Michigan Cancer Foundation-7 cells (MCF-7) are isolated breast cancer cells (Studebaker, *et al.*, 2008; Baumgarten and Frasar, 2012), high level of IL-6 in MCF-7 cells induces the epithelial-to-mesenchymal transition (EMT), and increases their invasiveness (Sullivan and others 2009) . Further, IL-6 is associated with angiogenesis by optimize of its ability to induce the mRNA of vascular endothelial growth factor (VEGF), which is typically a direct angiogen Chavey C, *et al.*, (2007) Also another study showed the displayed role of (IL-6) that induced the expression of vascular endothelial growth factor and referred to over expression of (IL-6) in human basal cell carcinoma lines increases antiapoptotic activity and tumorigenic potency (Cohen T., *et al.*, (1996) Jee SH, *et al.*, (2001). Relationship between IL-6 with vascular endothelial growth factor in cervical cancer the, these findings point to an important role of IL-6 in the progression of breast cancer at least in patients with advanced disease (Wei LH, *et al.*, 2001).

Level of IL-6 relation to hormone receptors (ER, PR and HER2)

In the current study we investigated the relationship of (IL-6) hormone receptors in (BC) samples, we observed an association of levels of IL-6 with ER, PR the result showed increased mean level of (IL-6) with positive (ER+) as compared with negative (ER-) with high significant differences at ($p=.000$), and increased in (PR+) receptors as compared with (PR-) also with high significant differences ($p=.000$), these results may be regarded that the (IL-6) associated with (ER)(PR) and (HER2) receptors which it was mammary markers, and this results agreed with (Fontanini G., *et al.*, 1999) who observed, level of IL-6 was expression directly associated with the expression of ER, PR that symbolize important mammary differentiation markers, ER-positive tumors were also reactive with IL-6 ($P=.02$), and the percentage of ER-positive cells was directly related to that of IL-6-positive cells ($P.00005$), same the results were obtained with regard to the percentages of PR-positive cells ($P=.025$). The possible contact between interleukins and steroid hormones has been suggested by (Reed, *et al.*, 1992) on breast cyst fluid, they were observed that IL-1 and IL-6 caused increase of estrogen synthesis through stimulating aromatase

and estradiol dehydrogenase activities in (BC) cells,(ER-) positive human breast cancer cells express the IL-6 receptor and their proliferation was inhibited by addition of IL-6, Chen *et al.*,(1988) and Chiu *et al.*,(1996), Also study by (Young A.,*etal.*,2013)whose observed an association on (IL-6 and IL-8) level with (BC) recurrence; these associations differed according to tumor subtype. other studies have established that cytokines can enhance, inhibit, or have no effect on cell proliferation and differentiation depending on the cell type examined, implying that the role of cytokines in mediation of tumor growth could be affected by tumor subtype every tumor subtype, may correspond differently with the immune system and produce a distinct cytokine profile these findings estimate that IL-6 may stimulate tumor cell motility and invasion for enhancement of metastasis of tumor cells Bazzoni and Beutler ,(1996); Salgado R.,*etal.*,(2003); Knupfer and Preiss ,(2007) ; Also(IL-6) chemoattracting and mitogenic for promotion of tumor growth, like IL-6, role in stimulates the growth and invasiveness of (MCF-7) breast cancer cells (Studebaker ,*etal.*,2008; Baumgarten and Frasor, 2012), High level of IL-6 in MCF-7 cells induces the epithelial-to-mesenchymal transition (EMT), and increases their invasiveness (Sullivan and others 2009).(Gilbert and Slingerland,2013),also IL-6 can increase aromatase activity, promote estrogen production, and, thus, stimulate progression of (ER+) (BC) (Chiu *et al.*,1996) ; (Catalano S,*etal.*,2003) and (Catalano S ,*etal.*,2004) Recently(Iliopoulos, *et al.*,2011) demonstrated that IL-6 links inflammation to malignant transformation by constitutively activating the(nuclear factor kappa-light-chain-enhancer of activated B cells) NF-κB pathway which in turn drives further IL-6 production creating a positive feedback loop and (Sasser ,*etal.*, 2007),they referred that cancer cell lines produce IL-6, of which ER-negative cells secrete more levels than ER-positive cells , IL-6 induces proliferation and a more aggressive phenotype in ER-positive cells ,also while (Buyse *et al.*, 2006); Sorlie *et al.*, (2001), they displayed A clear and well-characterized inverse correlation exists between breast cancer ER status and IL-6. This result may be clarified the role of (IL-6) with cell growth, proliferation ,differentiation and the over expression of(HER2) interact with immune system and lead to induced tumor growth , this result agreed with the studies showed increased with (IL-6) level in relation to patients with (HER2-) negative receptor (Young Ae.,*etal.*,2013; Sherif A.,*etal.*,2016). Moreover, the recent study found that the levels of IL-6 in breast recurrence may differ according to HER2 status ,as well as levels of IL-6 showed a positive association with breast cancer recurrence only among patients with (HER2-) tumors with high mean as compared to patients with HER2+ ,our results deal with study made by Sahlia B.,*etal.*,(2011) whose observed high level of IL-6 associated with HER2- in patients of BC ,other study done by Young Ae.,*etal.*,(2013) showed that increased level of IL-6 in HER2- with BC patients ,similarly ,our results agree with Egyptian study done by Sherif A.,*etal.*,(2016) ,they observed level of IL-6 may increased and correlate with HER2-,As known HER2 is a transmembrane tyrosine kinase

receptor that mediates growth, differentiation, and survival of cells; overexpression of HER2 at the cell membrane may lead to activation of multiple signaling complexes Kumar S,*etal.*,(2003).Some studies have reported different immune-mediated mechanisms according to patients' HER2 status and implied that abnormal expression of HER2 in breast tissue may affect the complex interaction between cancer and the immune response (Chavey C,*etal.*,2007). Moreover (IL-6) is able to induce epithelial-mesenchymal transitions (EMT) which has been implicated in generation of stem cell phenotype (Iliopoulos *et al.*, 2011; Mani *et al.*, 2008; Sullivan *et al.*,2009). Our results disagree with result of other researchers that referred to high level of (IL-6) associated with (HER2+) as compared with (HER2-) (Fontanini G.,*etal.*,1999; Hartman ,*et al.*, 2011).

REFERENCES

- 1-Kolahdoozan, S., Sadjadi, A., Radmard, A.R., & Khademi, H. (2010). Five common cancers in Iran. *Archives of Iranian Medicine*, 13(2), 143–6.
- 2-Fields, R.D. (2009) .New culprits in chronic pain . *Sci. AM* Pp 50-58.
- 3-Cadoo ,KA., Fournier ,MN.,Morris, PG. (2013) . Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. *The Quarterly Journal of Nuclear Medicine and Molecular Imaging* 57:312-321.
- 4-Shao ,R., Cao, S.,Wang, X., Feng ,Y., Billig, H.(2014) . The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. *American Journal of Translational Research* 6:104-113.
- 5-Onitilo, A.A., Engel, J.A., Greenlee, R.T. and Mukesh, B.N. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. *Clin. Med. Res.*, 7: 4-13.
- 6-Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM *et al* (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst* 98: 1183-92.
- 7-Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, Witteman J, Uitterlinden AG, Coebergh JW, Hofman A *et al* (2006). Interleukin 6 G-174 C polymorphism and breast cancer risk. *Eur J Epidemiol* 21: 373-6.
- 8-Kishimoto T (2006). Interleukin-6: discovery of a pleiotropic cytokine. *Arthritis Res Ther* 8 Suppl 2: S2
- 9-Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 inducesthe expression of vascular endothelial growth factor. *J Biol Chem* 1996,271:736-741.
- 10-Reed MJ, Coldham NG, Patel SR, Ghilcchick MW and James VHT (1992)Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. *J Endocrinol* 132: R5–R8.

- 11-Culig Z. 2011. Cytokine disbalance in common human cancers. *Biochim Biophys Acta* 1813(2):308–314
- 12-Baumgarten SC.,Fraser J.2012. Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. *Mol Endocrinol* 26(3):360–371.
- 13-De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E,Catalano G. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. *J Interferon Cytokine Res* 2001;21:45–52.
- 14-Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy.*Immunol Rev* 2004;202:275–93.
- 15-Roberto SALGADO, Sara JUNIUS, Ina BENOY, Peter VAN DAM, Peter VERMEULEN, Eric VAN MARCK, Philippe HUGET and Luc Y. DIRIX (2003) CIRCULATING INTERLEUKIN-6 PREDICTS SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER *Int. J. Cancer: 103*, 642–646 (2003) 2002 Wiley-Liss, Inc.
- 16-Lis CG, Grutsch JF, Vashi PG, CA. L: Is serum albumin an independent predictor of survival in patients with breast cancer? *J Parenter Enteral Nutr* 2003, 27:10-15
- 17-Cho YA, Sung MK, Yeon JY, Ro J, Kim J: Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. *Cancer research and treatment : official journal of Korean Cancer Association* 2013, 45(3):210-219.
- 18-Victor Pontoh, Daniel Sampepajung, Andi Asadul Islam, Mochammad Hatta. Profile of mRNA Expression of IL-6 and IL-10 in Breast Cancer Patients with or Without Chemotherapy. *American Journal of Clinical and Experimental Medicine*. Vol. 3, No. 3, 2015, pp. 99-104. doi: 10.11648/j.ajcem.20150303.15
- 19-Gilbert C. A., Slingerland J. M. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. *Annual Review of Medicine*. 2013;64:45–57. doi: 10.1146/annurev-med-121211-091527.
- 20-Choi Y., Lee H. J., Jang M. H., et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. *Human Pathology*. 2013;44(11):2581–2589. doi: 10.1016/j.humpath.2013.07.003.
- 21-Mani S. A., Guo W., Liao M.-J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*. 2008;133(4):704–715. doi: 10.1016/j.cell.2008.03.027.
- 22-Lee J.-K., Park S.-R., Jung B.-K., et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. *PLoS ONE*. 2013;8(12) doi: 10.1371/journal.pone.0084256.e84256
- 23-Arango Duque, Guillermo, and Albert Descoteaux. “Macrophage Cytokines: Involvement in Immunity and Infectious Diseases.” *Frontiers in Immunology* 5 (2014): 491. *PMC*. Web. 15 Feb. 2017. doi: 10.3389/fimmu.2014.00491
- 24-Hong D. S., Angelo L. S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. *Cancer*. 2007;110(9):1911–1928. doi: 10.1002/cncr.22999.
- 25-Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM (2007). Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. *Faseb J* 21: 3763-70.
- 26-Zhang GJ, Adachi I (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. *Anticancer Res* 19: 1427-32.
- 27-Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. *Gynecol Oncol* 2001;82:49–56.
- Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, et al. (2003) Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. *Am J Pathol* 163: 2531-2541.
- 28-Knupfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). *Breast Cancer Res Treat* 102: 129-135.
- 29-Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. *N Engl J Med* 334: 1717-1725.
- 30-Ordemann J, Jacobi CA, Braumann C, Schwenk W, Volk HD, et al. (2002) Immunomodulatory changes in patients with colorectal cancer. *Int J Colorectal Dis* 17: 37-41.
- 31-Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. *Rocz Akad Med Białymst* 48: 82-84.
- 32-Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, et al. (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. *Breast Cancer Res* 9: R15.
- Wise GJ, Marella VK, Talluri G, Shirazian D: Cytokine variations in patients with hormone treated prostate cancer. *J Urol* 2000, 164:722-725.
- 33-De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G: Serum levels of interleukin 6 as a prognostic factor in advanced non small cell lung cancer. *Oncol Rep* 1998, 5:649-652.
- 34-Praveen Ravishankaran, R Karunanithi2Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients *World Journal of Surgical Oncology* 2011, 9:18 <http://www.wjso.com/content/9/1/18>

- 35-Brozek W, Bises G, Girsch T, et al. Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumor progression. *Eur J Cancer*. 2005; 41: 2347-2354.
- 36-Bellone S, Watts K, Cane S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. *Gynecol Oncol*. 2005; 98: 92-98.
- 37-Songur N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. *Tumor*. 2004;90: 196-200.
- 38-Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. *Ann Surg Oncol*. 2000; 7: 133-138.
- 39-Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6. *J Clin Oncol*. 2005; 23: 1044-1045.
- 40-Zakrzewska I, Pozański J. Changes of serum IL-6 and CRP after chemotherapy in patients with ovarian carcinoma. *Pol Merk Lek*. 2001; 11: 210-213.
- 41-Garcia-Tunon I, Ricote M, Ruiz A, et al. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. *Histopathology*. 2005; 47: 82-89.
- 42-Kamińska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I – an independent prognostic factor. *Tumor Biol*. 2005; 26: 186-194.
- 43-Nikiteas NI, Tzanakis N, Gazouli M. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. *World J Gastroenterol*. 2005;11: 1639-1643.
- 44-Zhang G, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. *Anticancer Res*. 1999; 19: 1427-1432.
- 45-Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. *J Biol Chem* 283:14665-14673.
- 46-Fuksiewicz M, Kaminska J, Kotowicz B, Kowalska M, Rubach M, et al. (2006) Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. *Clin Chem Lab Med* 44: 1092-1097
- 47-Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER (1996) Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. *Mol Cell Endocrinol* 118:215-220.
- 48-Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. *Rocz Akad Med Białymst* 48: 82-84.
- 49-Jiang XP, Yang DC, Elliott RL, Head JF (2000) Reduction in serum IL-6 after vaccination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. *Cytokine* 12:458-465.
- 50-Bellone S, Watts K, Cane S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. *Gynecol Oncol*. 2005; 98: 92-98.
- 51-Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst* 98:1183-1192.
- 52-Iliopoulos D, Hirsch HA, Wang G, Struhl K: Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. *Proc Natl Acad Sci U S A* 2011,108(4):1397-1402.
- 53-Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. *J Biol Chem*. 2003;278:28668-76.
- 54-Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. *J Biol Chem*. 2004;279:19908-15.
- 55-Sherif A. Ibrahim, , Eslam A. El-Ghonaimy, Hebatallah Hassan, Noha Mahana, Mahmoud Abdelbaky Mahmoud, Tahani El-Mamlouk, Mohamed El-Shinawi, Mona M. Mohamed. (2016) Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression: Cairo University *Journal of Advanced Research*: (2016) vol:7,pp 661-670 .
- 56-Chen JQ, Russo PA, Cooke C, Russo IH, Russo J: ERbeta shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in estrogen-induced synthesis of mitochondrial respiratory chain proteins. *Biochim Biophys Acta* 2007, 1773(12):1732-1746.

57-Young Ae Cho, Mi-Kyung Sung, Jee-Young Yeon,

Jungsil Ro, Jeongseon Kim, 2013Prognostic Role of Interleukin-6, Interleukin-8, and Leptin Levels according to Breast Cancer Subtype *Cancer Res Treat.* 2013;45(3):210-219 <http://www.cancerresearchandtreatment.org>

58-G Fontanini, D Campani, M Roncella, D Cecchetti, S Calvo, A Toniolo and F Basolo(1999) Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma *British Journal of Cancer* 80(3/4), 579–584,1999 *Cancer Research Campaign Article no. bjoc.1998.0394*

59-Hartman Z, Yang X, Glass O, Lei G, Osada T, Dave SS, et al. HER2 overexpression elicits proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. *Cancer Res.* 2011;71:4380–4391.

60-Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, *et al.* (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 98:10869-10874.

61-Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, *et al.* (2008)Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. *Cancer Res* 68:9087-9095.

62-Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, *et al.* (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. *Oncogene* 28:2940-2947.

Salhia B, Tapia C, Ishak EA, et al (2011). Molecular subtype analysis determines the association of advanced breast cancer I Egypt with favorable biology. *BMC Womens Health*, 11, 44-52. *Saudi Cancer Registry*

63-Ferlay J, Soerjomataram I, Ervik M, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 136, 359-86.

64- Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. *Cancer.* 1991;68:2142-9.